Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.

For patients with metastatic urothelial carcinoma who are platinum refractory, and for those patients who are not candidates for cisplatin, immunotherapy is the current standard of care.